200 mg/m 2 melphalan-the gold standard for multiple myeloma Journal Article
| Author: | Giralt, S. |
| Article Title: | 200 mg/m 2 melphalan-the gold standard for multiple myeloma |
| Keywords: | cancer survival; treatment outcome; survival analysis; overall survival; lenalidomide; thalidomide; clinical trial; drug tolerability; neutropenia; doxorubicin; drug dose reduction; cancer radiotherapy; drug megadose; progression free survival; bortezomib; infection; multiple myeloma; dexamethasone; melphalan; vincristine; autologous stem cell transplantation; age factors; cancer regression; whole body radiation; radiation dose fractionation; disease progression; antineoplastic agents, alkylating; cancer relapse; short survey; cancer control; interleukin 6 antibody; great britain |
| Journal Title: | Nature Reviews Clinical Oncology |
| Volume: | 7 |
| Issue: | 9 |
| ISSN: | 1759-4774 |
| Publisher: | Nature Publishing Group |
| Date Published: | 2010-09-01 |
| Start Page: | 490 |
| End Page: | 491 |
| Language: | English |
| DOI: | 10.1038/nrclinonc.2010.104 |
| PUBMED: | 20798699 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Export Date: 20 April 2011" - "Source: Scopus" |
